BiogenvsMerck & Company

BIIB and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BIIB

Biogen Inc.

$251.41

Value $36.9B

+0.25%
BIIB's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Biogen (BIIB) has a market value of $36.9B and Merck & Company (MRK) $341B. Over the last year, with dividends, BIIB moved +52.7% and MRK +52.7%. The P/E is 106.2 for BIIB and 138.9 for MRK. Dividend yield: BIIB none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BIIB$36.9B

    MRK$341B

    MRK is 9.2 times BIIB

  • Revenue, 12 months

    BIIB$10.3B

    MRK$67.4B

    MRK is 6.5 times BIIB

  • Net income, 12 months

    BIIB$348M

    MRK$2.5B

    MRK is 7.1 times BIIB

  • Operating margin

    BIIB–

    MRK–

  • ROIC

    BIIB1.3%

    MRK3.9%

    2.6 points apart

  • P/E

    BIIB106.2

    MRK138.9

    MRK is 1.3 times BIIB

  • Dividend yield

    BIIB0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    BIIB-2.7%

    MRK+94.3%

    97.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BIIB-2.7%

MRK+94.3%

5010015020020222023202420252026
Returns by period
PeriodBIIBWith dividendsMRKWith dividends
1 year since November 17, 2025+52.7%Price +52.7%+52.7%Price +48.4%
3 years since November 17, 2023+10.3%+3.3% a yearPrice +10.3%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021-2.7%-0.5% a yearPrice -2.7%+94.3%+14.2% a yearPrice +66.8%
10 years since November 18, 2016-20.7%-2.3% a yearPrice -20.7%+216.6%+12.2% a yearPrice +133.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BIIBBiogenMRKMerck & Company

Valuation

BIIBMRK
Valuation
Price$251.41$137.78
Market value$36.9B$341B
Enterprise value (EV)$42.9B$385B
P/E106.2138.9
P/E, 5-year median20.014.8
P/B2.07.6
EV/EBIT96.480.8
Free cash flow yield5.6%4.3%

Results and growth

BIIBMRK
Results and growth
Revenue, 12 months$10.3B$67.4B
Net income, 12 months$348M$2.5B
Free cash flow, 12 months$2.1B$14.7B
Earnings per share, 12 months$2.32$0.98
Revenue growth, year on year2.2%1.3%
Revenue growth a year, past-6.0%over 5 years+9.4%over 5 years
EPS growth a year, past-18.7%over 5 years+21.2%over 5 years

Margins and returns on capital

BIIBMRK
Margins and returns on capital
Gross margin74.0%71.8%
Operating margin––
Net margin3.4%3.6%
ROIC1.3%3.9%
ROE1.9%5.2%

Balance sheet

BIIBMRK
Balance sheet
Cash$1.3B$9.7B
Total debt$7.4B$53.8B
Net debt / EBITDA4.95.7
Interest cover1.5×2.4×

Dividends and buybacks

BIIBMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BIIB or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Biogen or Merck & Company?

By market value, Merck & Company ($341B) is about 9.2 times Biogen ($36.9B), at today's prices.

How did BIIB and MRK stock do over the last 10 years?

Since November 18, 2016, BIIB's price moved -20.7% and MRK's +133.4%. With dividends: BIIB -20.7% (-2.3% a year), MRK +216.6% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, BIIB or MRK?

The dividend yield at today's price is none for Biogen and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of BIIB and MRK?

At today's price, the P/E is 106.2 for BIIB and 138.9 for MRK. The median of the last five years was 20.0 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Biogen or Merck & Company?

Over the last twelve months, the net margin was 3.4% for Biogen and 3.6% for Merck & Company, and the operating margin – and –. Revenue was $10.3B and $67.4B.

Which is the better investment, Biogen or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.